Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | +5.50% | +2.22% | -20.69% |
Financials (USD)
Sales 2024 * | 149M | Sales 2025 * | 192M | Capitalization | 191M |
---|---|---|---|---|---|
Net income 2024 * | -16M | Net income 2025 * | 18M | EV / Sales 2024 * | 1.28 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.99 x |
P/E ratio 2024 * |
-13.1
x | P/E ratio 2025 * |
13.4
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.89% |
Latest transcript on Rigel Pharmaceuticals, Inc.
1 day | +5.50% | ||
1 week | +2.22% | ||
Current month | +9.52% | ||
1 month | -14.18% | ||
3 months | -4.17% | ||
6 months | +44.24% | ||
Current year | -20.69% |
Managers | Title | Age | Since |
---|---|---|---|
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 00-03-31 |
Dean Schorno
DFI | Director of Finance/CFO | 61 | 18-05-28 |
Chief Tech/Sci/R&D Officer | - | 16-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gregg Lapointe
CHM | Chairman | 65 | 17-11-01 |
Gary Lyons
BRD | Director/Board Member | 73 | 05-09-30 |
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 00-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 509 M€ | -.--% | ||
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 1.15 | +5.50% | 783,238 |
24-05-01 | 1.09 | +3.81% | 746,810 |
24-04-30 | 1.05 | -1.87% | 1,045,916 |
24-04-29 | 1.07 | -2.73% | 2,122,707 |
24-04-26 | 1.1 | 0.00% | 364,286 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.69% | 191M | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- RIGL Stock